Literature DB >> 4163982

Pneumocystis carinii pneumonia.

G Ivady, L Paldy, M Koltay, G Toth, Z Kovacs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 4163982     DOI： 10.1016/s0140-6736(67)90464-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Pneumocystis carinii pneumonia after 40 years.

Authors:  M Nouza
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

Review 2.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

3.  Thymic alymphoplasia, monoclonal gammopathy, and Pneumocystis carinii pneumonia in an infant.

Authors:  D M Becroft; R Douglas
Journal:  Arch Dis Child       Date:  1968-08       Impact factor: 3.791

4.  Pneumocystis carinii pneumonia and reticuloses.

Authors:  K R Humphries; H Ngan; K James
Journal:  Thorax       Date:  1968-01       Impact factor: 9.139

Review 5.  Pneumocystis carinii pneumonia.

Authors:  J T Macfarlane; R G Finch
Journal:  Thorax       Date:  1985-08       Impact factor: 9.139

6.  Treatment of pneumocystis carinii pneumonia in children.

Authors:  A Lipson; W C Marshall; A R Hayward
Journal:  Arch Dis Child       Date:  1977-04       Impact factor: 3.791

7.  Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds.

Authors:  Melanie T Cushion; Peter D Walzer; Margaret S Collins; Sandra Rebholz; Jean Jacques Vanden Eynde; Annie Mayence; Tien L Huang
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 8.  Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia.

Authors:  K L Goa; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.